Cartesian Therapeutics (RNAC) Receivables (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Receivables data on file, last reported at $261000.0 in Q1 2026.

• On a quarterly basis, Receivables fell 85.21% year-over-year to $261000.0 in Q1 2026; TTM through Mar 2026 was $261000.0, a 85.21% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, up 27.87% from the prior year.
• Receivables for Q1 2026 stood at $261000.0, down from $1.1 million in the prior quarter.
• Over the last five years, Receivables for RNAC reached as high as $35.5 million in Q2 2024 and fell as low as $261000.0 in Q1 2026.
• Historically, Receivables has averaged $7.6 million across 5 years, with a median of $6.4 million in 2023.
• Across the five-year window, Receivables jumped 451.41% in 2024 and plunged 99.0% in 2025, its largest moves.
• Year by year, Receivables stood at $9.8 million in 2022, then retreated by 9.29% to $8.9 million in 2023, then slumped by 90.15% to $872000.0 in 2024, then gained by 27.87% to $1.1 million in 2025, then plunged by 76.59% to $261000.0 in 2026.
• Per Business Quant data, the three most recent Receivables figures were $261000.0 in Q1 2026, $1.1 million in Q4 2025, and $722000.0 in Q3 2025.